ELECTRORETINOGRAPHY IN AGE-RELATED MACULAR DEVELOPMENT

这项研究中的共同投资人参与了一个多中心 评估激光疗效的随机试验 光凝预防严重视力丧失的临床研究 老年性黄斑变性(AMD)合并 中心凹下新生血管膜。作为参与的成员 临床中心，联合调查人员预计有100人符合条件 每年有新的中心凹下膜的患者将 随机分为治疗组和不治疗组。 每年将有大约50名患者参加 复发的新生血管膜。 黄斑中心凹光凝辅助研究的目的 研究(FPS)是利用图形视网膜电信号作为 黄斑功能的客观、易量化的测量 这些病人。PERG将从每位患者的 注册时间，注册后3个月和6个月，以及 在FPS研究期间，每6个月进行一次。 七个检查大小，对应于空间频率范围 从每度0.05到3.0个周期，将在Pattera中显示 反转率分别为2赫兹和30赫兹。黄斑病变进展 将对每一组患者进行随时间推移的退化评估 通过确定与PERG相关的函数的参数 潜伏到空间频率。因为每个病人都必须有 学习眼的视力不高于20/80且不低于 超过20/320有资格参加试验计划，补充措施 需要对黄斑功能进行评估以帮助评估治疗效果。 初步工作表明，PERG函数提供了一种 “视网膜敏锐度”的客观测量，与视觉质量有关， 在视力低下的患者中很容易测量到，并且 来访之间的可变性。预计这一方法将是 不仅在评估治疗效果方面有价值 FPS审判的背景，但在未来也将有价值 AMD患者的治疗试验。

Co-investiagtors in this study are participating in a multicenter randomized trial to assess the effectiveness of laser photocoagulation in preventing of delaying severe visual loss in age-related macular degeneration (AMD) complicated by a subfoveal neovascular membrane. As members of a participating clinical center, the co-investigators anticipate 100 eligible patients each year with new subfoveal membranes will be randomly assigned to treatment/no treatment groups. Approximately 50 patients per year will be enrolled with recurrent neovascular membranes. The purpose of this ancillary study to the Foveal Photocoagulation Study (FPS) is to utilize the pattern electroretinogram as an objective, readily-quantifiable measure of macular function in these patients. PERGs will be obtained from each patient at the time of enrollment, at 3 and 6 months following enrollment, and every 6 months thereafter for the duration of the FPS study. Seven check sizes, corresponding to spatial frequencies ranging from 0.05 to 3.0 cycles per degree, will be presented at pattern reversal rates of 2 Hz and 30 Hz. Progression of macular degeneration over time will be assessed in each group of patients by determining the parameters of functions relating PERG ampitude to spatial frequency. Since each patient must have visual acuity in the study eye no better than 20/80 and no worse than 20/320 to be eligible for the trail, supplementary measures of macular function are needed to help assess treatment efficacy. Preliminary work has shown that PERG function provides an objective measure of "retinal acuity", relates to quality of vision, is readily measurable in patients with low vision, and has low intervisit variability. It is anticipated that this approach will be of value not only in the assessment of treatment efficacy within the context of the FPS trial, but also will be of value in future treatment trials in patients with AMD.